Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Public ClinicalTrials.gov record NCT04211363. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.
Study identification
- NCT ID
- NCT04211363
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 439 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2019 (Actual)
- Primary completion
- Nov 16, 2020 (Actual)
- Completion
- Nov 16, 2020 (Actual)
- Last update posted
- Dec 7, 2022
2019 – 2020
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcutis Biotherapeutics Clinical Site 127 | Encinitas | California | 92024 | — |
| Arcutis Biotherapeutics Clinical Site 112 | Fremont | California | 94538 | — |
| Arcutis Biotherapeutics Clinical Site 120 | Irvine | California | 92697 | — |
| Arcutis Biotherapeutics Clinical Site 123 | San Diego | California | 92123 | — |
| Arcutis Biotherapeutics Clinical Site 136 | San Francisco | California | 94132 | — |
| Arcutis Biotherapeutics Clinical Site 118 | Delray Beach | Florida | 33484 | — |
| Arcutis Biotherapeutics Clinical Site 131 | Miami | Florida | 33174 | — |
| Arcutis Biotherapeutics Clinical Site 137 | Ocala | Florida | 34470 | — |
| Arcutis Biotherapeutics Clinical Site 105 | Sanford | Florida | 32771 | — |
| Arcutis Biotherapeutics Clinical Site 114 | Plainfield | Illinois | 46168 | — |
| Arcutis Biotherapeutics Clinical Site 102 | Rolling Meadows | Illinois | 60008 | — |
| Arcutis Biotherapeutics Clinical Site 111 | Baton Rouge | Louisiana | 70809 | — |
| Arcutis Biotherapeutics Clinical Site 125 | Rockville | Maryland | 20850 | — |
| Arcutis Biotherapeutics Clinical Site 138 | Rockville | Maryland | 20850 | — |
| Arcutis Biotherapeutics Clinical Site 101 | Brighton | Massachusetts | 02135 | — |
| Arcutis Biotherapeutics Clinical Site 116 | Clinton Township | Michigan | 48038 | — |
| Arcutis Biotherapeutics Clinical Site 139 | Reno | Nevada | 89509 | — |
| Arcutis Biotherapeutics Clinical Site 129 | East Windsor | New Jersey | 08520 | — |
| Arcutis Biotherapeutics Clinical Site 121 | New York | New York | 10029 | — |
| Arcutis Biotherapeutics Clinical Site 130 | Rochester | New York | 14623 | — |
| Arcutis Biotherapeutics Clinical Site 108 | Stony Brook | New York | 11790 | — |
| Arcutis Biotherapeutics Clinical Site 115 | High Point | North Carolina | 27262 | — |
| Arcutis Biotherapeutics Clinical Site 124 | Fairborn | Ohio | 45324 | — |
| Arcutis Biotherapeutics Clinical Site 134 | Oklahoma City | Oklahoma | 73118 | — |
| Arcutis Biotherapeutics Clinical Site 128 | Duncansville | Pennsylvania | 16635 | — |
| Arcutis Biotherapeutics Clinical Site 113 | Exton | Pennsylvania | 19003 | — |
| Arcutis Biotherapeutics Clinical Site 135 | Pittsburgh | Pennsylvania | 15213 | — |
| Arcutis Biotherapeutics Clinical Site 104 | College Station | Texas | 77845 | — |
| Arcutis Biotherapeutics Clinical Site 119 | Dallas | Texas | 75246 | — |
| Arcutis Biotherapeutics Clinical Site 110 | San Antonio | Texas | 78218 | — |
| Arcutis Biotherapeutics Clinical Site 117 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04211363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2022 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04211363 live on ClinicalTrials.gov.